Où docteurs et entreprises se rencontrent
Menu
Connexion

Vous avez déjà un compte ?

Nouvel utilisateur ?

Mot de passe oublié

Internship position in Leukemia Research (Master student)

ABG-85430 Stage master 2 / Ingénieur 6 mois 500
13/05/2019
Logo de
Luxembourg Institute of Health
Strassen Grand Est Luxembourg
  • Biologie
Tumor Stroma Interactions, Leukemia, molecular biology, cell culture
31/10/2019

Établissement recruteur

Luxembourg Institute of Health (LIH) is the leading public research center in Luxembourg for basic, pre-clinical and clinical research in biomedicine and public health. Our clinically-oriented biomedical research activities in Oncology, Infection & Immunity and Population Health encompass the generation of knowledge on the pathogenesis, diagnosis and treatment of diseases with large impacts on public health and the epidemiological surveillance of these diseases. With the mission to deliver scientific, economic and societal value for Luxembourg, LIH aims to translate knowledge into clinical applications impacting on healthcare systems while shaping personalized medicine.

Description

Background: Chronic Lymphocytic Leukemia (CLL) represent the most frequent leukemia in adults. Despite recent advances in treatments, CLL remains a deadly uncurable disease. This cancer is caracterized by an accumulation of abnormal, apoptosis resistant, B lymphocytes in the blood and lymphoid organs of the patients. CLL progression is highly dependent on complex interactions between tumor cells and their microenvironment. Indeed, CLL cells can modify stromal cells and immune cells to promote their survival and to escape from the immune surveillance system.

Objectives: Our team focuses on the mechanisms leading to leukemia progression, in particular the influence of CLL cells on stromal cells and immune cells located in their microenvironment, with the goal to identify new prognostic markers and therapeutic targets.

Training and research environment. Tumor Stroma Interactions research group is a dynamic and multinational team whose current members originate from France, Belgium, Germany and Italy. It belongs to the Department of Oncology, whose research activities focus on the cellular and molecular mechanisms of tumor progression using a wide range of cutting edge technologies, including mass cytometry, transcriptomic and proteomic analyses, as well as in vitro and in vivo techniques using state-of-the art animal models for cancer research. Master students will assist one of our projects that aims to explore the interplay between leukemic cells and their microenvironment, and will be co-supervised by Dr. E. Moussay (PI), Dr. J. Paggetti (PI) and experienced scientists from the team.

Recent related reference (open access): Paggetti J, et al. Exosomes released by chronic lymphocytic leukemia cells induce cancer-associated fibroblast formation. Blood 126(9):1106-17.

Wierz M, et al. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood 131(14):1617-1621. (IF:15.132)

What we offer and conditions

  • Students will have the opportunity to work in an interactive and international scientific environment, attend conferences by eminent scientists from abroad, and present their own work during lab meetings.
  • They will receive training in basic biochemistry, molecular and cell biology techniques, such as Western-blotting, real-time PCR, and cell culture, as well as confocal imaging, flow cytometry and in vivo experiments on mouse models.
  • Mouse  experimentation practice and FELASA (or equivalent) diploma would be considered as an asset.
  • Applicants must be affiliated to their own University.
  • English is mandatory.
  • Master 2 students will receive 500€/month unless they have their own funding source, e.g. Erasmus grant.

Profil

Master students, affiliated to their own University

Prise de fonction

01/01/2020
Partager via
Postuler
Fermer

Vous avez déjà un compte ?

Nouvel utilisateur ?


Mot de passe oublié
Besoin d'informations ?

Vous souhaitez recevoir une ou plusieurs lettres d’information de l’ABG. Chaque mois des actualités, des offres, des outils, un agenda…

item1
item1
Ils nous font confiance